PBYI
Puma Biotechnology Inc

6,880
Mkt Cap
$246.16M
Volume
330,627.00
52W High
$6.12
52W Low
$2.58
PE Ratio
6.60
PBYI Fundamentals
Price
$4.84
Prev Close
$4.89
Open
$4.95
50D MA
$5.03
Beta
0.83
Avg. Volume
438,584.35
EPS (Annual)
$0.6166
P/B
2.14
Rev/Employee
$1.34M
Loading...
Loading...
News
all
press releases
Connor Clark & Lunn Investment Management Ltd. Buys 68,567 Shares of Puma Biotechnology, Inc. $PBYI
Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 8.2% during the 2nd quarter, according to the company in its...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Director Sells $97,200.00 in Stock
Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Michael Patrick Miller sold 20,000 shares of the stock in a transaction dated Tuesday, November 11th. The stock was sold at an...
MarketBeat·5d ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Director Michael Patrick Miller Sells 20,000 Shares
Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Michael Patrick Miller sold 20,000 shares of Puma Biotechnology stock in a transaction dated Tuesday, November 11th. The stock was...
MarketBeat·6d ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Releases Quarterly Earnings Results, Beats Estimates By $0.12 EPS
Puma Biotechnology (NASDAQ:PBYI - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.21 EPS for the quarter, topping analysts' consensus...
MarketBeat·11d ago
News Placeholder
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 5, 2025, the Compensation Committee of Pumas Board of Directors approved the grant of inducement...
Business Wire·13d ago
News Placeholder
PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised
Puma Biotechnology beats third-quarter estimates for earnings and revenues and lifts its 2025 outlook on stronger Nerlynx sales.
Zacks·13d ago
News Placeholder
Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates
Puma Biotech (PBYI) delivered earnings and revenue surprises of +133.33% and +12.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
Puma Biotechnology Inc. Q3 Profit Decreases, But Beats Estimates
(RTTNews) - Puma Biotechnology Inc. (PBYI) revealed earnings for third quarter that Decreased from the same period last year but beat the Street estimates...
Nasdaq News: Markets·14d ago
News Placeholder
Puma Biotechnology Reports Third Quarter 2025 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2025. Unless otherwise stated, all comparisons are for the...
Business Wire·14d ago
News Placeholder
Acadia Pharmaceuticals (ACAD) Q3 Earnings and Revenues Top Estimates
Acadia (ACAD) delivered earnings and revenue surprises of +85.71% and +1.84%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago

Latest PBYI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.